In the last trading session, 1.14 million shares of the Cellectar Biosciences Inc (NASDAQ:CLRB) were traded, and its beta was 0.51. Most recently the company’s share price was $0.25, and it changed around $0.0 or 1.53% from the last close, which brings the market valuation of the company to $11.66M. CLRB currently trades at a discount to its 52-week high of $3.42, offering almost -1268.0% off that amount. The share price’s 52-week low was $0.22, which indicates that the current value has risen by an impressive 12.0% since then. We note from Cellectar Biosciences Inc’s average daily trading volume that its 10-day average is 0.81 million shares, with the 3-month average coming to 947.82K.
Cellectar Biosciences Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.33. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 2 recommended CLRB as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight.
Cellectar Biosciences Inc (NASDAQ:CLRB) trade information
Instantly CLRB has showed a green trend with a performance of 1.53% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.2740 on recent trading dayincreased the stock’s daily price by 8.76%. The company’s shares are currently down -15.42% year-to-date, but still down -1.02% over the last five days. On the other hand, Cellectar Biosciences Inc (NASDAQ:CLRB) is -18.42% down in the 30-day period. We can see from the shorts that 1.56 million shares have been sold at a short interest cover period of 2.19 day(s).
The consensus price target as assigned by Wall Street analysts is $12, which translates to bulls needing to increase their stock price by 97.92% from its current value. Analyst projections state that CLRB is forecast to be at a low of $12 and a high of $12.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 40.27%. Cellectar Biosciences Inc earnings are expected to increase by 53.01% in 2025, but the outlook is positive 19.07% per year for the next five years.
CLRB Dividends
Cellectar Biosciences Inc’s next quarterly earnings report is expected to be released on 2025-May-12.
Cellectar Biosciences Inc (NASDAQ:CLRB)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.71% of Cellectar Biosciences Inc shares, and 12.42% of them are in the hands of institutional investors. The stock currently has a share float of 12.63%. Cellectar Biosciences Inc stock is held by 36.0 institutions, with AIGH CAPITAL MANAGEMENT LLC being the largest institutional investor. By 2024-06-30, it held 8.4764% of the shares, which is about 3.04 million shares worth $6.86 million.
ROSALIND ADVISORS, INC., with 7.5535% or 2.71 million shares worth $6.76 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 1.07 shares worth $0.27 million, making up 2.33% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held roughly 568.75 shares worth around $0.14 million, which represents about 1.23% of the total shares outstanding.
